XML 84 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Segment Information | Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by the CODM are reported on the condensed consolidated statements of earnings for the periods ended September 30, 2025 and 2024. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included. The following table details AbbVie’s worldwide net revenues:
|  | Three months ended September 30, |  | Nine months ended September 30, |  |  |  |  |  |
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |  |
Skyrizi | United States | $ | 4,085 |  |  | $ | 2,778 |  |  | $ | 10,847 |  |  | $ | 6,774 |  |  |  |  |  |  |
| International | 623 |  |  | 427 |  |  | 1,709 |  |  | 1,166 |  |  |  |  |  |  |
| Total | $ | 4,708 |  |  | $ | 3,205 |  |  | $ | 12,556 |  |  | $ | 7,940 |  |  |  |  |  |  |
Rinvoq | United States | $ | 1,559 |  |  | $ | 1,170 |  |  | $ | 4,231 |  |  | $ | 2,912 |  |  |  |  |  |  |
| International | 625 |  |  | 444 |  |  | 1,699 |  |  | 1,225 |  |  |  |  |  |  |
| Total | $ | 2,184 |  |  | $ | 1,614 |  |  | $ | 5,930 |  |  | $ | 4,137 |  |  |  |  |  |  |
Humira | United States | $ | 619 |  |  | $ | 1,765 |  |  | $ | 2,165 |  |  | $ | 5,896 |  |  |  |  |  |  |
| International | 374 |  |  | 462 |  |  | 1,129 |  |  | 1,415 |  |  |  |  |  |  |
| Total | $ | 993 |  |  | $ | 2,227 |  |  | $ | 3,294 |  |  | $ | 7,311 |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |  |
Vraylar | United States | $ | 931 |  |  | $ | 873 |  |  | $ | 2,592 |  |  | $ | 2,338 |  |  |  |  |  |  |
| International | 3 |  |  | 2 |  |  | 7 |  |  | 5 |  |  |  |  |  |  |
| Total | $ | 934 |  |  | $ | 875 |  |  | $ | 2,599 |  |  | $ | 2,343 |  |  |  |  |  |  |
Botox Therapeutic | United States | $ | 825 |  |  | $ | 708 |  |  | $ | 2,323 |  |  | $ | 1,988 |  |  |  |  |  |  |
| International | 160 |  |  | 140 |  |  | 456 |  |  | 422 |  |  |  |  |  |  |
| Total | $ | 985 |  |  | $ | 848 |  |  | $ | 2,779 |  |  | $ | 2,410 |  |  |  |  |  |  |
Ubrelvy | United States | $ | 344 |  |  | $ | 261 |  |  | $ | 907 |  |  | $ | 685 |  |  |  |  |  |  |
| International | 10 |  |  | 8 |  |  | 25 |  |  | 18 |  |  |  |  |  |  |
| Total | $ | 354 |  |  | $ | 269 |  |  | $ | 932 |  |  | $ | 703 |  |  |  |  |  |  |
Qulipta | United States | $ | 252 |  |  | $ | 168 |  |  | $ | 661 |  |  | $ | 442 |  |  |  |  |  |  |
| International | 36 |  |  | 8 |  |  | 87 |  |  | 15 |  |  |  |  |  |  |
| Total | $ | 288 |  |  | $ | 176 |  |  | $ | 748 |  |  | $ | 457 |  |  |  |  |  |  |
Vyalev | United States | $ | 53 |  |  | $ | — |  |  | $ | 81 |  |  | $ | — |  |  |  |  |  |  |
| International | 85 |  |  | 28 |  |  | 218 |  |  | 55 |  |  |  |  |  |  |
| Total | $ | 138 |  |  | $ | 28 |  |  | $ | 299 |  |  | $ | 55 |  |  |  |  |  |  |
Duodopa | United States | $ | 16 |  |  | $ | 24 |  |  | $ | 56 |  |  | $ | 72 |  |  |  |  |  |  |
| International | 80 |  |  | 87 |  |  | 233 |  |  | 267 |  |  |  |  |  |  |
| Total | $ | 96 |  |  | $ | 111 |  |  | $ | 289 |  |  | $ | 339 |  |  |  |  |  |  |
Other Neuroscience | United States | $ | 42 |  |  | $ | 54 |  |  | $ | 148 |  |  | $ | 172 |  |  |  |  |  |  |
| International | 4 |  |  | 2 |  |  | 12 |  |  | 11 |  |  |  |  |  |  |
| Total | $ | 46 |  |  | $ | 56 |  |  | $ | 160 |  |  | $ | 183 |  |  |  |  |  |  |
|  | Three months ended September 30, |  | Nine months ended September 30, |  |  |  |  |  |
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |
Imbruvica | United States | $ | 507 |  |  | $ | 618 |  |  | $ | 1,579 |  |  | $ | 1,823 |  |  |  |  |  |  |
| Collaboration revenues | 199 |  |  | 210 |  |  | 619 |  |  | 676 |  |  |  |  |  |  |
| Total | $ | 706 |  |  | $ | 828 |  |  | $ | 2,198 |  |  | $ | 2,499 |  |  |  |  |  |  |
Venclexta | United States | $ | 341 |  |  | $ | 340 |  |  | $ | 974 |  |  | $ | 921 |  |  |  |  |  |  |
| International | 385 |  |  | 337 |  |  | 1,108 |  |  | 1,007 |  |  |  |  |  |  |
| Total | $ | 726 |  |  | $ | 677 |  |  | $ | 2,082 |  |  | $ | 1,928 |  |  |  |  |  |  |
Elahere | United States | $ | 150 |  |  | $ | 139 |  |  | $ | 453 |  |  | $ | 331 |  |  |  |  |  |  |
| International | 20 |  |  | — |  |  | 55 |  |  | — |  |  |  |  |  |  |
| Total | $ | 170 |  |  | $ | 139 |  |  | $ | 508 |  |  | $ | 331 |  |  |  |  |  |  |
Epkinly | Collaboration revenues | $ | 44 |  |  | $ | 31 |  |  | $ | 129 |  |  | $ | 82 |  |  |  |  |  |  |
| International | 25 |  |  | 12 |  |  | 61 |  |  | 24 |  |  |  |  |  |  |
| Total | $ | 69 |  |  | $ | 43 |  |  | $ | 190 |  |  | $ | 106 |  |  |  |  |  |  |
Other Oncology | United States | $ | 11 |  |  | $ | — |  |  | $ | 13 |  |  | $ | — |  |  |  |  |  |  |
Aesthetics |  |  |  |  |  |  |  |  |  |  |  |  |
Botox Cosmetic | United States | $ | 379 |  |  | $ | 414 |  |  | $ | 1,084 |  |  | $ | 1,253 |  |  |  |  |  |  |
| International | 258 |  |  | 257 |  |  | 801 |  |  | 780 |  |  |  |  |  |  |
| Total | $ | 637 |  |  | $ | 671 |  |  | $ | 1,885 |  |  | $ | 2,033 |  |  |  |  |  |  |
Juvederm Collection | United States | $ | 98 |  |  | $ | 105 |  |  | $ | 278 |  |  | $ | 349 |  |  |  |  |  |  |
| International | 155 |  |  | 153 |  |  | 466 |  |  | 549 |  |  |  |  |  |  |
| Total | $ | 253 |  |  | $ | 258 |  |  | $ | 744 |  |  | $ | 898 |  |  |  |  |  |  |
Other Aesthetics | United States | $ | 265 |  |  | $ | 272 |  |  | $ | 817 |  |  | $ | 828 |  |  |  |  |  |  |
| International | 38 |  |  | 38 |  |  | 128 |  |  | 119 |  |  |  |  |  |  |
| Total | $ | 303 |  |  | $ | 310 |  |  | $ | 945 |  |  | $ | 947 |  |  |  |  |  |  |
Eye Care |  |  |  |  |  |  |  |  |  |  |  |  |
Ozurdex | United States | $ | 32 |  |  | $ | 33 |  |  | $ | 92 |  |  | $ | 102 |  |  |  |  |  |  |
| International | 85 |  |  | 86 |  |  | 273 |  |  | 272 |  |  |  |  |  |  |
| Total | $ | 117 |  |  | $ | 119 |  |  | $ | 365 |  |  | $ | 374 |  |  |  |  |  |  |
Lumigan/Ganfort | United States | $ | 42 |  |  | $ | 58 |  |  | $ | 142 |  |  | $ | 129 |  |  |  |  |  |  |
| International | 55 |  |  | 58 |  |  | 164 |  |  | 181 |  |  |  |  |  |  |
| Total | $ | 97 |  |  | $ | 116 |  |  | $ | 306 |  |  | $ | 310 |  |  |  |  |  |  |
Alphagan/Combigan | United States | $ | 9 |  |  | $ | 26 |  |  | $ | 35 |  |  | $ | 54 |  |  |  |  |  |  |
| International | 38 |  |  | 36 |  |  | 108 |  |  | 116 |  |  |  |  |  |  |
| Total | $ | 47 |  |  | $ | 62 |  |  | $ | 143 |  |  | $ | 170 |  |  |  |  |  |  |
Other Eye Care | United States | $ | 138 |  |  | $ | 123 |  |  | $ | 399 |  |  | $ | 421 |  |  |  |  |  |  |
| International | 110 |  |  | 105 |  |  | 316 |  |  | 321 |  |  |  |  |  |  |
| Total | $ | 248 |  |  | $ | 228 |  |  | $ | 715 |  |  | $ | 742 |  |  |  |  |  |  |
Other Key Products |  |  |  |  |  |  |  |  |  |  |  |  |
Mavyret | United States | $ | 146 |  |  | $ | 147 |  |  | $ | 472 |  |  | $ | 458 |  |  |  |  |  |  |
| International | 166 |  |  | 155 |  |  | 521 |  |  | 562 |  |  |  |  |  |  |
| Total | $ | 312 |  |  | $ | 302 |  |  | $ | 993 |  |  | $ | 1,020 |  |  |  |  |  |  |
Creon | United States | $ | 368 |  |  | $ | 338 |  |  | $ | 1,127 |  |  | $ | 995 |  |  |  |  |  |  |
Linzess/Constella | United States | $ | 315 |  |  | $ | 225 |  |  | $ | 701 |  |  | $ | 693 |  |  |  |  |  |  |
| International | 11 |  |  | 9 |  |  | 31 |  |  | 28 |  |  |  |  |  |  |
| Total | $ | 326 |  |  | $ | 234 |  |  | $ | 732 |  |  | $ | 721 |  |  |  |  |  |  |
All other |  | $ | 660 |  |  | $ | 726 |  |  | $ | 2,010 |  |  | $ | 2,280 |  |  |  |  |  |  |
Total net revenues | $ | 15,776 |  |  | $ | 14,460 |  |  | $ | 44,542 |  |  | $ | 41,232 |  |  |  |  |  |  |
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), intangible assets impairment expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7).

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration